GILD
GILEAD SCIENCES, INC.
Nasdaq: GILD · Foster City, CA · Healthcare
$133.29-2.58 (-1.90%)Closed
Market Cap$165.41B
Cash$5.48Bmost recent
Runwayprofitable
P/E (TTM)19.7EPS $6.78
52-Wk Range$94.40 – $154.92
Avg Volume7.2M3-month
Price & Trading Activity

Daily close with catalyst overlays and trading volume

$133.29+112.0%
Pipeline

Drug candidates sponsored by GILEAD SCIENCES · ClinicalTrials.gov

71 drugs · 100 trials
PhaseDrug / CandidateIndicationsStatusNext CompletionTrials
Phase 4Atripla
HIV Infections
Completed
2009-10past
1
Phase 4Truvada
HIV Infections
Completed—1
Phase 3Viread (tenofovir disoproxil fumarate)
HIV Infections
Completed
2001-12past
1
Phase 3Adefovir Dipivoxil for oral suspension, 2 mg/mL
Chronic Hepatitis B
Completed
2006-03past
1
Phase 3TDF
Chronic Hepatitis B
Completed
2007-04past
1
Phase 2MBX-102
Type 2 Diabetes+1 more
Completed
2010-02past
2
Phase 3Tenofovir disoproxil fumarate (TDF)
Hepatitis B Virus (HBV)
Completed
2011-03past
1
Phase 3Ranolazine
Type 2 Diabetes Mellitus
Completed
2013-08past
1
Phase 3E/C/F/TAF
HIV+1 more
Completed
2014-08-26past
1
Phase 2EVG/COBI/FTC/TDF
Acquired Immunodeficiency Syndrome+1 more
Completed
2015-10-22past
1
Phase 3FTC/RPV/TAF
HIV-1 Infection
Completed
2016-06-22past
1
Phase 3Sofosbuvir
Chronic Hepatitis C+1 more
Completed
2016-08-12past
2
Phase 3IMMU-107
Metastatic Pancreatic Cancer+1 more
Terminated
2016-11past
1
Phase 3SOF
Hepatitis C+3 more
Completed
2018-06-21past
3
Phase 3Idelalisib
Chronic Lymphocytic Leukemia+6 more
Completed
2019-06-10past
4
Phase 3AZLI
Bronchiectasis+2 more
Completed
2020-05-27past
3
Phase 3Filgotinib
Psoriatic Arthritis
Terminated
2021-01-19past
1
Phase 3LDV/SOF
Chronic Hepatitis C Virus+4 more
Completed
2021-06-11past
5
Phase 3SEL
Nonalcoholic Steatohepatitis+1 more
Completed
2021-09-03past
3
Phase 3Remdesivir
COVID-19
Completed
2022-04-20past
2
Phase 3Cilofexor
Primary Sclerosing Cholangitis+2 more
Completed
2022-11-10past
2
Phase 3Obeldesivir
COVID-19
Completed
2024-02-23past
2
Phase 3Oral Lenacapavir (LEN)
Pre-Exposure Prophylaxis of HIV Infection
Active, not recruiting
2024-08-21past
1
Phase 3Seladelpar 10 mg
Primary Biliary Cholangitis+2 more
Completed
2025-02-24past
2
Phase 3Bictegravir
HIV-1-infection
Active, not recruiting
2025-10-27past
1
Phase 3TAF
Chronic Hepatitis B
Recruiting
2026-09
3
Phase 3Sacituzumab govitecan-hziy (SG)
Triple Negative Breast Cancer
Recruiting
2027-06
1
Phase 3Tenofovir disoproxil fumarate
HIV Infections
Completed—2
Phase 3ambrisentan
Pulmonary Arterial Hypertension
Completed—1
Phase 2Adefovir Dipivoxil
Hepatitis B+1 more
Completed
2005-05past
3
Phase 1veltuzumab
Non-Hodgkin's Lymphoma+2 more
Completed
2007-11past
1
Phase 2GS-9450
Nonalcoholic Steatohepatitis
Completed
2009-08past
1
Phase 1milatuzumab
Chronic Lymphocytic Lymphoma
Completed
2013-01past
1
Phase 2GS-5885 tablet
Hepatitis C, Chronic
Completed
2013-03past
1
Phase 1hLL1-DOX (the doxorubicin conjugate of milatuzumab)
Multiple Myeloma
Terminated
2013-07past
1
Phase 2Arhalofenate 600 mg
Gout
Completed
2015-01past
1
Phase 2BIC
HIV-1 Infection
Completed
2015-11-30past
1
Phase 2IMMU-132 infusion is administered to participants in one arm for the study
Triple-negative Breast Cancer
Withdrawn
2016-08past
1
Phase 2Simtuzumab
Idiopathic Pulmonary Fibrosis+1 more
Completed
2016-08-08past
2
Phase 2SOF/VEL
Hepatitis C Virus Infection
Completed
2017-07-28past
2
Phase 2Entospletinib MM
Chronic Lymphocytic Leukemia+4 more
Terminated
2017-09-14past
1
Phase 2Andecaliximab
Gastric Adenocarcinoma+1 more
Completed
2019-10-25past
2
Phase 2Teropavimab
HIV Infection
Active, not recruiting
2024-07-02past
1
Phase 2Magrolimab
Triple-Negative Breast Cancer
Terminated
2024-10-08past
1
Phase 1GS-4321
Chronic Hepatitis Delta
Recruiting
2029-02
1
Phase 1hMN14 (labetuzumab)
Colorectal Cancer+6 more
Completed—2
Phase 1GS-6620
Hepatitis C, Chronic
Completed
2011-10past
1
Phase 1AB0024
Neoplasms
Completed
2012-03past
1
Phase 1RANEXA
Severe Renal Impairment
Terminated
2012-08past
1
Phase 1TF2/IMP288
Metastatic Colorectal Cancer
Withdrawn
2013-02past
1
Phase 1GS-7340
Chronic Hepatitis B
Completed
2013-04past
1
Phase 1Treatment A
Chronic Lymphocytic Leukemia
Completed
2013-08past
1
Phase 1Tirabrutinib
Non Hodgkins Lymphoma+1 more
Completed
2015-02-23past
1
Phase 1Selonsertib
Diabetic Kidney Disease
Completed
2015-12-15past
1
Phase 1GS-4774
Healthy Volunteers+1 more
Completed
2017-08-14past
2
Phase 1Alobresib
Solid Tumors and Lymphomas
Completed
2017-10-11past
1
Phase 1Hu5F9-G4
Acute Myeloid Leukemia+1 more
Completed
2018-11past
1
Phase 1Entospletinib
Hematologic Malignancy+1 more
Terminated
2019-02-26past
1
Phase 1KITE-439
Human Papillomavirus (HPV) 16+ Relapsed/Refractory Cancer
Terminated
2022-02-18past
1
Phase 1Oral Lenacapavir
HIV-1 Infection
Completed
2022-06-09past
1
Phase 1GS-4528
Solid Tumor
Active, not recruiting
2026-07
1
Phase 1Sacituzumab Govitecan-hziy
Advanced or Metastatic Solid Tumor+1 more
Recruiting
2026-12
1
Phase 1GS-0151
Rheumatoid Arthritis
Recruiting
2027-03
1
Phase 1Adefovir
HIV Infections
Completed—1
N/AHepsera
Hepatitis B
Completed
2006-04past
1
N/AUnnamed
Hepatitis B+1 more
Completed
2012-10past
1
N/AInfluenza Vaccine
B-cell Malignancies
Terminated
2019-10-09past
1
N/AUnnamed
HIV-1-infection
Completed
2022-03-21past
1
N/AUnnamed
Chronic Hepatitis B
Completed—1
N/AAztreonam lysine
Cystic Fibrosis+1 more
Approved For Marketing—1
N/ACidofovir
Cytomegalovirus Retinitis+1 more
Unknown—1
Valuation

Risk-adjusted NPV

Loading pipeline…
Peer comparison

Cohort check

Large-cap biotech · 5 tickers
Loading peers…
Cells tinted green are top-ranked in the cohort, red are worst-ranked.